Larvol Delta - Bambusa-plans-to-disclose-data-from-the-ongoing-placebocontrolled-4week-Phase-1b2a-trial-of-BBT001-in-patients-with-moderate-to-severe-atopic-dermatitis-in-the-middle-of-2026

BBT001 - Bambusa Therapeutics

https://www.prnewswire.com/news-releases/bambusa-therapeutics-presented-positive-results-from-the-phase-1-multiple-ascending-dose-trial-of-bbt001-at-the-2026-american-academy-of-dermatology-aad-annual-meeting-302731280.html

Apr 1, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next